What is the expert's option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey

European Journal of Neurology

Volumn 19, Issue 1, 2012, Pages 163-167

  Kraemer, M ^a   Berlit, P ^a   Diesner, F ^a   Khan, N ^b  

^a ALFRIED KRUPP KRANKENHAUS   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiplatelet therapy; Moyamoya disease; Survey

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ARTICLE; ASIAN; CONSERVATIVE TREATMENT; HEALTH SURVEY; HUMAN; MICROCIRCULATION; MICROEMBOLISM; MOYAMOYA DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVASCULARIZATION; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME;

ASIAN CONTINENTAL ANCESTRY GROUP; DATA COLLECTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXPERT TESTIMONY; HUMANS; MOYAMOYA DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS;

EID: 84155167802     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03481.x     Document Type: Article

References (26)

1. Kraemer M, Berlit P. Primary central nervous system vasculitis and moyamoya disease: similarities and differences. J Neurol 2010; 257: 816-819.
2. Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans. Stroke 2008; 39: 3193-3200.
3. Kramer M, Berlit P. [Moyamoya disease - a rare vasculopathy in Europeans]. Fortschr Neurol Psychiatr 2010; 78: 542-550; quiz 551.
4. Krischek B, Kasuya H, Khan N, Tatagiba M, Roder C, Kraemer M. Genetic and clinical characteristics of Moyamoya disease in Europeans. Acta Neurochir Suppl 2011; 112: 31-34.
5. Yonekawa Y, Fandimo J, Hug M, Wiesli M, Fujioka M, Khan N. Moyamoya angiopathy in Europe. In: Cho BK, Tominaga T, eds. Moyamoya Disease Update. New York: Springer, 2010: 361-369.
6. Hallemeier CL, Rich KM, Grubb RL Jr, et al. Clinical features and outcome in North American adults with moyamoya phenomenon. Stroke 2006; 37: 1490-1496.
7. Suzuki J, Kodama N. Moyamoya disease - a review. Stroke 1983; 14: 104-109.
8. Graham JF, Matoba A. A survey of moyamoya disease in Hawaii. Clin Neurol Neurosurg 1997; 99(Suppl. 2): S31-S35.
9. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 2005; 36: 2148-2153.
10. Imaizumi T, Hayashi K, Saito K, Osawa M, Fukuyama Y. Long-term outcomes of pediatric moyamoya disease monitored to adulthood. Pediatr Neurol 1998; 18: 321-325.
11. Khan N, Yonekawa Y. Moyamoya angiopathy in Europe: the beginnings in Zurich, practical lessons learned, increasing awareness and future perspectives. Acta Neurochir Suppl 2008; 103: 127-130.
12. Khan N, Schuknecht B, Boltshauser E, et al. Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir (Wien) 2003; 145: 1061-1071; discussion 1071.
13. Vajkoczy P. Moyamoya disease: collateralization is everything. Cerebrovasc Dis 2009; 28: 258.
14. Czabanka M, Vajkoczy P, Schmiedek P, Horn P. Age-dependent revascularization patterns in the treatment of moyamoya disease in a European patient population. Neurosurg Focus 2009; 26: E9.
15. Khan N, Dodd R, Marks MP, Bell-Stephens T, Vavao J, Steinberg GK. Failure of primary percutaneous angioplasty and stenting in the prevention of ischemia in moyamoya angiopathy. Cerebrovasc Dis 2011; 31: 147-153.
16. Andaluz N, Choutka O, Zuccarello M. Trends in the management of adult moyamoya disease in the United States: results of a nationwide survey. World Neurosurg 2010; 73: 361-364.
17. Yonekawa Y, Kahn N. Moyamoya disease. Adv Neurol 2003; 92: 113-118.
18. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG. Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 1997; 99(Suppl. 2): S58-S60.
19. Weigele JB, Taylor RA, Kasner SE. Current management of symptomatic intracranial stenosis: medical versus endovascular therapy. Curr Atheroscler Rep 2007; 9: 296-304.
20. Chiu D, Shedden P, Bratina P, Grotta JC. Clinical features of moyamoya disease in the United States. Stroke 1998; 29: 1347-1351.
21. Khan N, Yonekawa Y. Moyamoya angiopathy in Europe. Acta Neurochir Suppl 2005; 94: 149-152.
22. Numaguchi Y, Gonzalez CF, Davis PC, et al. Moyamoya disease in the United States. Clin Neurol Neurosurg 1997; 99(Suppl 2): S26-S30.
23. Guzman R, Lee M, Achrol A, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. J Neurosurg 2009; 111: 927-935.
24. Guzman R, Steinberg GK. Moyamoya Disease in North America. In: Cho BK, Tominaga T, eds. Moyamoya Disease Update. New York: Springer, 2010: 353-360.
25. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 2008; 79: 900-904.
26. Horn P, Lanczik O, Vajkoczy P, et al. Hemodynamic reserve and high-intensity transient signals in moyamoya disease. Cerebrovasc Dis 2005; 19: 141-146.